Peter R. Carroll, MD, MPH

Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer; Taube Family Distinguished Professorship in Urology, UCSF

Associate Director, Strategic Planning and Clinical Services; and Program Leader, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine; Chair, Department of Urology, UCSF

Cancer Center Program Membership

Prostate Cancer

Research Summary

My main research interests include identifying clinical and pathologic determinants of prostate cancer recurrence, progression, and mortality; discovering novel biomarkers for prostate cancer diagnostics and prognostics; developing evidence-based guidelines for improved management of prostate cancer patients; and examining the impact of lifestyle on health-related quality of life and survivorship among men with prostate cancer. Since 1995, I have been PI of CaPSURE™, a national disease registry study of over 14,000 men with prostate cancer treated at 40+ sites. At UCSF, we have developed a novel program in clinical management of and research on active surveillance for men with low-burden prostate cancer. We are committed to reducing the burden of prostate cancer treatment (physical, psychological and monetary). In 2007, I and colleagues initiated the Prostate Cancer Active Surveillance Study (PASS), a large multi-institutional cohort of men on active surveillance, designed to examine quantitative metabolic, molecular, and physiologic imaging biomarkers and lifestyle factors as novel predictors of prostate cancer progression. We aim to better determine which patients may safely avoid radical treatment, while concurrently identifying men who may benefit from early treatment instead of active surveillance.

Research Funding

  • September 30, 2008 - July 31, 2018 - UCSF KURe Career Development Program, Co-Principal Investigator. Sponsor: NIH/NIDDK, Sponsor Award ID: K12DK083021
  • August 5, 1999 - September 29, 2012 - Cancer Center Support Grant, Co-Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: P30CA082103
  • September 30, 2009 - August 31, 2012 - Effectiveness of Early Stage Prostate Cancer Treatment, Principal Investigator. Sponsor: NIH/NCI, Sponsor Award ID: RC1CA146596
  • September 30, 2006 - September 29, 2011 - Male Reproductive Health Research Career Development Program, Principal Investigator. Sponsor: NIH/NICHD, Sponsor Award ID: K12HD053943


University of California, Berkeley, BA, 1974, Zoology
Georgetown University School of Medicine, Washington, D.C., MD, 1979, Medicine
University of California, Berkeley, MPH, 2008

Honors & Awards

  • Other Experience and Professional Memberships
  • 2002-present
    American Urological Association, Prize Essay Committee (Chair)
  • 2002-2008
    American Urological Association, Update Series Advisory Committee (member)
  • 2001-present
    American Board of Urology, Trustee, President Elect (2006-2008)
  • 2001-present
    American College of Surgeons Commission on Cancer, AUA representative
  • 2000-present
    American Association of Genitourinary Surgeons, Site Committee
  • 2003-present
    American Association of Genitourinary Surgeons, Councilor
  • 2004-present
    ASCO Prostate Cancer Committee, Symposium Committee
  • 2004-present
    ASCO, Oncology Taskforce
  • 2005-present
    ASCO, Cancer Communications Committee, Roster of Cancer Experts
  • 2005-present
    American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative
  • 2006-present
    The Journal of Urology, Associate Editor
  • 2011 – present
    AUA Update, Editor
  • Honors:
  • 2001
    Ken and Donna Derr - Chevron Endowed Chair in Prostate Cancer
  • 2002
    Clinical Society of the American Association of Genitourinary Surgeons
  • 2004
    Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer
  • 2010
    AUA Eugene Fuller Triennial Prostate Award
  • 2010
    Society of Urologic Oncology Medal
  • 2014
    Barringer Medal, American Association of Genitourinary Surgeons

Selected Publications

  1. de la Calle CM, Shee K, Chu CE, Cowan JE, Nguyen HG, Carroll PR. Association of Age with Risk of Adverse Pathological Findings in Men Undergoing Delayed Radical Prostatectomy Following Active Surveillance. Urology. 2021 Jun 09.  View on PubMed
  2. Salavati A, Gencturk M, Koksel Y, Schik AN, Carroll PR, Feng FY, Rowe SP, Lawhn-Heath C, Hope TA, Froelich JW. A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria? Eur J Nucl Med Mol Imaging. 2021 Jun 06.  View on PubMed
  3. Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Mohamad O, Cowan JE, Feng FY, Carroll PR, Trock BJ, Partin AW, D'Amico AV. Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. J Clin Oncol. 2021 Jun 04; JCO2003714.  View on PubMed
  4. Greenberg SA, Washington SL, Lonergan PE, Cowan JE, Baskin AS, Nguyen HG, Odisho AY, Simko JP, Carroll PR. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum PSA. J Urol. 2021 Apr 27; 101097JU0000000000001793.  View on PubMed
  5. Maggi M, Del Giudice F, Falagario UG, Cocci A, Russo GI, Di Mauro M, Sepe GS, Galasso F, Leonardi R, Iacona G, Carroll PR, Cooperberg MR, Porreca A, Ferro M, Lucarelli G, Terracciano D, Cormio L, Carrieri G, De Berardinis E, Sciarra A, Busetto GM. SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. Cancers (Basel). 2021 Apr 23; 13(9).  View on PubMed
  6. Salciccia S, Capriotti AL, Laganà A, Fais S, Logozzi M, De Berardinis E, Busetto GM, Di Pierro GB, Ricciuti GP, Del Giudice F, Sciarra A, Carroll PR, Cooperberg MR, Sciarra B, Maggi M. Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. Int J Mol Sci. 2021 Apr 22; 22(9).  View on PubMed
  7. Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ, OSPREY Study Group . Reply by Authors. J Urol. 2021 Apr 15; 101097JU000000000000169802.  View on PubMed
  8. Langlais CS, Chan JM, Kenfield SA, Cowan JE, Graff RE, Broering JM, Carroll P, Van Blarigan EL. Post-diagnostic coffee and tea consumption and risk of prostate cancer progression by smoking history. Cancer Causes Control. 2021 Apr 09.  View on PubMed
  9. Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Eur Urol. 2021 Jun; 79(6):717-721.  View on PubMed
  10. Gaylis FD, Cooperberg MR, Chen RC, Malin J, Loeb S, Witte JS, Carroll PR, Cohen ES, Dato PE, Lin DW, Zheng Y, Seibert TM, Setzler C, Wilt W, Gomez SL, Chan JML, Catalona WJ. Defining Quality Metrics for Active Surveillance: The Michigan Urological Surgery Improvement Collaborative Experience. Letter. J Urol. 2021 Apr 05; 101097JU0000000000001781.  View on PubMed
  11. Carroll PR, Maggi M. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. Reply. J Urol. 2021 Mar 08; 101097JU0000000000001711.  View on PubMed
  12. Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW, Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021 Mar 03; 11(1):5040.  View on PubMed
  13. Tan WP, Rastinehad AR, Klotz L, Carroll PR, Emberton M, Feller JF, George AK, Gill IS, Gupta RT, Katz AE, Lebastchi AH, Marks LS, Marra G, Pinto PA, Song DY, Sidana A, Ward JF, Sanchez-Salas R, Rosette J, Polascik TJ, Focal Therapy Consensus group. . Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. Urol Oncol. 2021 Mar 03.  View on PubMed
  14. Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, Saperstein L, Preston MA, Alva AS, Patnaik A, Durack JC, Stambler N, Lin T, Jensen J, Wong V, Siegel BA, Morris MJ. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol. 2021 07; 206(1):52-61.  View on PubMed
  15. Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, Piert M, Iagaru A, Pollard JH, Wong V, Jensen J, Lin T, Stambler N, Carroll PR, Siegel BA, CONDOR Study Group . Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res. 2021 Jul 01; 27(13):3674-3682.  View on PubMed
  16. Merriel SWD, Moon D, Dundee P, Corcoran N, Carroll P, Partin A, Smith JA, Hamdy F, Moore C, Ost P, Costello T. A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. BMC Urol. 2021 Feb 04; 21(1):18.  View on PubMed
  17. Chu CE, Cowan JE, Lonergan PE, Washington SL, Fasulo V, de la Calle CM, Shinohara K, Westphalen AC, Carroll PR. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2021 Jan 19.  View on PubMed
  18. Chan JM, Van Blarigan EL, Langlais CS, Zhao S, Ramsdill JW, Daniel K, Macaire G, Wang E, Paich K, Kessler ER, Beer TM, Lyons KS, Broering JM, Carroll PR, Kenfield SA, Winters-Stone KM. Feasibility and Acceptability of a Remotely Delivered, Web-Based Behavioral Intervention for Men With Prostate Cancer: Four-Arm Randomized Controlled Pilot Trial. J Med Internet Res. 2020 12 31; 22(12):e19238.  View on PubMed
  19. Carroll PR. Editorial Comment. J Urol. 2021 03; 205(3):777-778.  View on PubMed
  20. Smith R, Liu M, Liby T, Bayani N, Bucher E, Chiotti K, Derrick D, Chauchereau A, Heiser L, Alumkal J, Feiler H, Carroll P, Korkola JE. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. Sci Rep. 2020 12 10; 10(1):21750.  View on PubMed

Go to UCSF Profiles, powered by CTSI